logo
Lab-grown seafood is hitting restaurant menus. Would you eat it?

Lab-grown seafood is hitting restaurant menus. Would you eat it?

Washington Post28-06-2025
The dinner special at Kann, a Haitian restaurant in Portland, features cubes of salmon with pickled strawberries and spiced tomatoes. It's served with a rice cracker and a bold claim: 'Be the first in the world to taste the future of sustainable seafood.'
The Coho salmon, pinkish orange and streaked with lines of white fat, wasn't wild-caught in Alaska or farmed in Chile. It comes from cells grown in tanks at a former microbrewery in San Francisco, and in late May it became the first cell-cultured seafood to receive safety approval from the U.S. Food and Drug Administration.
This salmon is intended to be consumed raw, like sushi, or cured, as in ceviche. Kann is the first restaurant to offer it, incorporating it in that light summer dish. Austin-based chef Yoshi Okai served it as sashimi at the Aspen Food & Wine Classic this month and will be including it in the omakase lineup at his Texas restaurant starting in mid July.
At least two lab-grown chicken products have previously gotten the FDA's green light. But the okay for the salmon, made by California-based Wildtype, marks a significant milestone for the alternative protein industry, which has been working to produce substitutes for traditional meat and fish that can help meet the world's growing demand for food while minimizing environmental and climate impacts.
'We're not looking to put fishermen out of business, we are not looking to eliminate the need for fish farming,' said Justin Kolbeck, a Wildtype co-founder. 'The amount of seafood that is currently in demand, and where it's projected to go, are so high we actually need all of the production that we're doing from those other tools, plus ours, plus maybe some help from the plant-based world, to be able to meet that demand.'
While alternative protein can be made from plants or fermentation, cultivated seafood primarily comes from animal cells. Cells are isolated from specific species, providing the material needed to establish continually usable cell lines.
At Wildtype, cells derived from Pacific salmon are grown in big steel tanks and fed with a mix of nutrients, including amino acids, vitamins, salts, sugars, proteins and fats.
'Imagine kind of a fancy Gatorade,' Kolbeck said.
He described how the cells are then rinsed in a centrifuge and transferred into a commercial kitchen, where they're mixed with plant-based ingredients to help create form and structure and provide further nutritional elements.
The entire process takes about two weeks to create a 220-gram, uniformly cut block of fish.
By comparison, it can take at least two years for a living salmon to mature.
Seafood, especially fish, is a key source of protein for billions of people around the world — a number that is projected to rise significantly in the coming years. One 2021 study estimated that global fish consumption will increase nearly 80 percent by 2050.
But wild stocks are being threatened by overfishing, and while farmed seafood has helped alleviate some of that burden, aquaculture can have its own environmental challenges.
Human-made alternatives could be particularly helpful for popular types of seafood, such as tuna and salmon, said Max Valentine, senior scientist and director of Oceana's illegal fishing and transparency campaign. 'It shouldn't be seen as the Holy Grail to save oceans, but I do think it would provide an avenue for alternatives to reduce pressure,' she said.
'We're addressing food security,' said Lou Cooperhouse, founder and president of BlueNalu, a San Diego-based company making cell-cultured bluefin tuna. 'Wildtype's approval was really great for the whole industry.'
These sorts of products could also be options for consumers who are wary of contaminants that may be found in wild-caught and farmed fish, said Aryé Elfenbein, a Wildtype co-founder.
What's more, cell-cultured seafood could help cut down on waste, since lab-cultivated blocks of protein can be used in their entirety and don't create leftover scraps.
'The first slice is the same as the last slice,' Kolbeck said.
Some proponents of lab-grown seafood have touted additional environmental benefits, including fewer emissions and less harm to ocean ecosystems.
Cooperhouse said making BlueNalu's sushi tuna toro product requires energy and water but that the company's estimated footprint 'pales in comparison' to the impact of commercial fishing.
While BlueNalu and other companies have done assessments of their environmental impact, some experts say an accurate picture might not be possible without production facilities being at full scale.
'I haven't seen any really comprehensive life cycle analysis on the comparison of this technology to other technologies,' said Sebastian Belle, president of the National Aquaculture Association, a trade group. 'At the end of the day, that's really what we need to really understand is it better or is it the same or is it worse? And we need do that science.'
For cell-cultivated seafood to really take off, there needs to be an appetite for it.
'We're just beginning this journey, and the big question that everybody has is what will the consumer response be?' Belle said.
Consumer interest in alternative proteins has appeared to plateau in recent years. Meanwhile, several states have moved to ban cell-derived meat, and in certain cases, such as Florida, have broadened restrictions to include seafood. In turn, some cultivated seafood companies say it has been challenging to entice investors.
'A lot of potential investors, I think, are trepidatious,' Kolbeck said. 'Specifically those who maybe have had some investments in the plant-based space that haven't penned out well and haven't had a great return, they look at this and are like, is this the same thing? Is it not?
'Objectively, capital is a lot harder to find today than it was four years ago,' he continued.
These fish alternatives must match wild-caught or farmed options on price, taste, texture and nutrition, Valentine said. When she tried a lab-grown salmon product several years ago, she said the texture wasn't the same as a traditional filet.
'It kind of gives uncanny valley,' she said. 'It's not quite fish, it's something else.'
But companies such as Wildtype saythey can give consumers what they want.
'Because we're making the product literally from the cell up, we can tune a lot of things based on consumer feedback, like shape, strength of the flavor, even the color,' Kolbeck said. 'Texture is a little bit harder, but it's also something that we could work on. … All of those things are things that we can actually change.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Top Stock Movers Now: Dayforce, Novo Nordisk, First Solar, and More
Top Stock Movers Now: Dayforce, Novo Nordisk, First Solar, and More

Yahoo

time8 minutes ago

  • Yahoo

Top Stock Movers Now: Dayforce, Novo Nordisk, First Solar, and More

Key Takeaways Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and comments from Federal Reserve Chair Jerome Powell due later in the week. Novo Nordisk shares climbed after the Food and Drug Administration approved the drugmaker's popular Wegovy weight-loss medicine to treat a serious liver disease. Dayforce shares surged following reports it's held talks about a takeover by private equity firm Thoma Bravo. Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and comments from Federal Reserve Chair Jerome Powell due later in the week. Dayforce (DAY) was the best-performing stock in the S&P 500 following a report that private equity firm Thoma Bravo is in discussions to acquire the human resources software provider. U.S.-listed shares of Novo Nordisk (NVO) also advanced after the Food and Drug Administration approved the drugmaker's popular Wegovy weight-loss medicine to treat a serious liver disease. First Solar (FSLR) and other solar stocks gained in the wake of new guidance from the Treasury Department on federal tax incentives for clean energy projects. Citi and Jefferies analysts said the release was better than anticipated. CVS Health (CVS) shares rose following an upgrade from UBS, which pointed to the drugstore and healthcare company's cost-cutting and improving healthcare benefits division. EQT (EQT) shares fell as the energy provider was downgraded from Roth Capital Partners on concerns an oversupply of natural gas will send prices down and hurt EQT's results. Oil and gold futures slid. The yield on the 10-year Treasury note was little changed. The U.S. dollar gained on the euro, pound, and yen. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets
Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets

Yahoo

time8 minutes ago

  • Yahoo

Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets

GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of Ozempic (semaglutide) and Wegovy (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx, effective immediately. GoodRx offers a platform for medication savings in the U.S. The collaboration significantly lowers the price available on GoodRx for two of the most in-demand GLP-1 medications nationwide, expanding access for those without adequate insurance move also marks the first time Ozempic has been made available to patients at this self-pay price. In the last year, almost 17 million people came to GoodRx looking for savings and information on GLP-1 medications, a 22% increase from the previous year. Now, GoodRx is poised to meet this growing demand more effectively. GoodRx research shows 19 million people lack coverage for any GLP-1s prescribed for weight loss. By filling the gaps in insurance coverage, GoodRx is playing a critical role in reducing friction in the system and helping accelerate speed to therapy so consumers can benefit from these critical treatments. Starting today, eligible patients can use GoodRx to self-pay for Ozempic and Wegovy pens for $499-per-month at over 70,000 retail pharmacies nationwide. In March, Novo Nordisk introduced NovoCare Pharmacy, a direct-to-patient delivery service to improve access to Wegovy for cash-paying patients. The program offers all dosage strengths of the weight-loss medication at a reduced price of $499 per month for uninsured individuals or those whose insurance does not cover obesity treatments. In June, Eli Lilly and Co. (NYSE:LLY) announced that the highest approved doses of Zepbound (tirzepatide), 12.5 mg and 15 mg, would soon be available in single-dose vials for $499 per month through LillyDirect's Self Pay Pharmacy Solutions and the Zepbound Self Pay Journey Program. Healthcare providers began prescribing the 12.5 mg and 15 mg vials on July 7; shipments to patients began in early August. With the addition of these doses, every strength of Zepbound vial will be available for $499/month or less ($349 for the 2.5 mg starter dose) to any eligible adult with obesity and a valid prescription, regardless of insurance. After the update, Hims & Hers Health Inc (NYSE:HIMS) stock is trading 2.35% lower at $44.94. In June, Novo Nordisk terminated its collaboration with Hims & Hers Health. On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity. Price Action: GDRX stock is trading higher by 30.83% to $4.880 at last check Monday. Read Next:Photo by KK Stock via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Corporate Technologies Acquires Cenetric in Kansas City, Expanding to Its 18th U.S. Market
Corporate Technologies Acquires Cenetric in Kansas City, Expanding to Its 18th U.S. Market

Yahoo

time8 minutes ago

  • Yahoo

Corporate Technologies Acquires Cenetric in Kansas City, Expanding to Its 18th U.S. Market

EDEN PRAIRIE, Minn., Aug. 18, 2025 /PRNewswire/ -- Corporate Technologies, a national leader in managed IT services, cybersecurity, and cloud solutions, has announced its acquisition of Cenetric, a Kansas City-based MSP serving small and mid-sized businesses. This marks Corporate Technologies' 18th market expansion as part of its ongoing nationwide growth strategy. Cenetric is recognized as one of the top 10 IT companies in the Kansas City area, as awarded by the Greater Kansas City Chamber of Commerce. "Brittany has built an exceptional business," said Jim Griffith, CEO of Corporate Technologies. "Cenetric's reputation and client-first approach make it a perfect fit. We're thrilled to welcome Brittany and her team." Brittany Fugate, Founder and CEO of Cenetric, said: "This partnership allows us to continue putting people first, both clients and employees, while gaining new capabilities. We're excited to join forces with a company that shares our values and vision." This acquisition is Corporate Technologies' eighth overall, and its third since partnering with Tonka Bay Equity Partners in July 2023. With this addition, Corporate Technologies continues to strengthen its position as a national provider focused on delivering proactive IT, cybersecurity, and cloud solutions to businesses across the U.S. About Corporate TechnologiesFounded in 1981, Corporate Technologies is a trusted provider of managed IT services, cybersecurity solutions, and disaster recovery for businesses nationwide. The company serves over 1,600 clients and is recognized for its commitment to customer success. Contact: Ugur Gulaydin, View original content to download multimedia: SOURCE Corporate Technologies, LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store